Anavex: Understanding Their Latest Alzheimer's Data News With Caution

Anavex: An Update To Their Phase 2b/3 Alzheimer's Trial Data

Annovis Bio: A Close Look At Their Parkinson's Trial Data

Annovis Bio: Searching For Efficacy In Alzheimer's Disease

Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead

A Close Look At Iovance Biotherapeutics' Accelerated Approval

Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown

DURECT: Reading Into AHFIRM Mortality Rates

Anavex: Additional P2b/3 Alzheimer's Trial Data Raises Additional Questions

Oramed: Buyer Beware

Evaluating Oramed After Their P3 Type 2 Diabetes Trial Failure

BioVie: Hold Your Enthusiasm

Anavex's Alzheimer's Results Leave Much To Be Desired

Buy Stoke Therapeutics At A Deep Discount Following Early Data In Dravet Syndrome

Krystal Biotech: A Buy For Growth Potential

Arcellx: Speculative Buy For Their 'Best-In-Class' CAR-T Cell Therapy

Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug

Started In 2016, Protalix's 2-Year Fabry Head-To-Head Trial Has Crossed The Finish Line

Amylyx's ALS Drug Application Hangs In The Balance

Protalix: Fabry BRIGHT Trial Data May Not Be So Bright After All

Anavex: The First Impression May Not Be The Right Impression

Cassava Sciences: Looking At SAVA From Both Sides Now

Krystal Biotech: Healing 'Butterfly Children' One Topical, Re-Dosable Gene Therapy At A Time

Cassava Sciences: Data Rules!

Krystal Biotech's Legal Risk: A Layperson's View